Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
Public ClinicalTrials.gov record NCT02658916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the long-term safety and tolerability of multiple intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy (PSP). The study will also assess the pharmacodynamic (PD) effects of BIIB092 on cerebrospinal fluid (CSF) N-terminal tau, pharmacokinetics (PK), and immunogenicity of BIIB092 in participants with PSP.
Study identification
- NCT ID
- NCT02658916
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 47 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 41 Years to 86 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2016 (Actual)
- Primary completion
- Mar 31, 2020 (Actual)
- Completion
- Mar 31, 2020 (Actual)
- Last update posted
- May 18, 2020
2016 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| University of California San Diego | La Jolla | California | 92037 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90024 | — |
| University of California, San Francisco, Medical Center at Parnassus | San Francisco | California | 94158 | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton, Inc. | Boca Raton | Florida | 33486 | — |
| University of Florida College of Medicine | Gainesville | Florida | 32607 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Minnesota Medical School | Minneapolis | Minnesota | 55455-0341 | — |
| Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901-1962 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104-4206 | — |
| The University of Texas Southwestern Medical Center | Dallas | Texas | 75390-8830 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02658916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02658916 live on ClinicalTrials.gov.